$2.79
▲ +0.3% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Overview
52-week range
$1.66
$4.54
39% of range
Avg surprise (last 3)
-8.2%
Avg reaction (last 2)
+3.8%
100% positive
Latest IV / EM
106%
EM ±24.2% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.26 | $-0.30 | +13.3% | +39.5% | +1.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.28 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.63 | $-0.41 | -53.7% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.43 | $-0.51 | +15.7% | — | +6.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.75 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.82 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.76 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.55 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.56 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.30 | -$0.63 | +52.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-25M | — | $-25M | $-52M | $-76M | — | $-66M | $-72M |
| Net income | $-25M | — | $-25M | $-53M | $-76M | — | $-62M | $-68M |
| EPS (diluted) | $-0.26 | — | $-0.28 | $-0.63 | $-0.92 | — | $-0.75 | $-0.82 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M |
| Total assets | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M |
| Long-term debt | $47M | $54M | $54M | $52M | $50M | $52M | — | — |
| Total liabilities | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M |
| Total equity | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M |